Efficacy and tolerability of long-term efavirenz plus nucleoside reverse transcriptase inhibitors for HIV-1 infection: Erratum

An error appeared in Fig. 1 of the article, which appeared in AIDS, volume 22, issue 2 [1].Fig. 1: Kaplan–Meier estimates of time to loss of virological response (< 400 copies/ml): randomized patients on initial therapy. Subjects considered to have reached the study endpoint at first virological rebound, change in antiretroviral therapy, or death. Subjects who remained in response at the time of discontinuation were censored at the date of their last on-study HIV-RNA measurement. Subjects who did not respond to initial treatment were considered to have reached the endpoint at time zero. Treatmentefavirenz, zidovudine plus lamivudine (EFV+ ZDV+ 3TC; N = 422);indinavir, zidovudine plus lamivudine (IDV+ZDV+3TC; N=415);efavirenz plus indinavir (EFV + IDV; N = 429).In Fig. 1, the legend on the bottom is incorrect. The bottom and middle lines on the graph were incorrectly labeled, and the last sentence of the legend should have read: Treatment efavirenz, zidovudine plus lamivudine (EFV+ ZDV+ 3TC; N= 422); indinavir, zidovudine plus lamivudine (IDV+ZDV+3TC; N = 415); efavirenz plus indinavir (EFV + IDV; N = 429). The corrected figure legend with the figure appears below.